Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, HER2-positive, PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.